Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus capecitabine in advanced hepatocellular carcinoma
2008-003972-23Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and capecitabine in hepatocellular carcinoma (HCC), sponsored by Leiden University Medical Center. Primary endpoints: Progression-free survival at 6 months and Biomarker assessment. Started Sep 2008; status: active.
02
Drugs
everolimuscapecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2008-003972-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003972-23.